Posts Tagged ‘pharmaceutical stocks’

« Older Entries
Newer Entries »

GIGA gallops, MSFT heavy volume, ICGN pained

Wednesday, December 1st, 2010

Gigatronics Inc. (NasdaqCM: GIGA) gained 18.72 percent to $2.60 at Wednesday’s close Volume was 103,119 shares, whereas its normal daily volume is 8,531. The San Ramon, Calif.-based GIGA announced today that it has received orders in excess of $4.8 million to supply microwave test equipment for the automation of production at contract manufacturers in China. The products supplied are part of Giga-tronics’ microwave signal switching family. These orders are expected to ship this Fiscal Year.

Microsoft Corp. (NasdaqGS: MSFT) Wednesday traded in 72,816,781 shares, slightly better its daily share average of 61,957,100. Shares nudged up 3.1 percent to $26.04. MSFT

Icagen Inc. (NasdaqGM: ICGN) dropped 13.76 percent in Wednesday afternoon trading, to $1.88, on volume of 2,640,381 shares, compared to its average daily volume of 171,532. The North Carolina-based ICGN today provided an update on its sodium channel program for pain and related disorders which is being conducted in collaboration with Pfizer. Based upon data obtained in this study, the companies have now selected one of these compounds to advance into further clinical studies. The selection of this compound has triggered a milestone payment to Icagen of $1.0 million.

Tags: , , , , ,
Posted in Technology Stocks | No Comments »

HSFT strong, GE active, MITL slumping

Wednesday, December 1st, 2010

Hi-Soft Technology International Ltd. (NasdaqGS: HSFT) gained 16.7 percent to $32.50 mid Wednesday afternoon. Volume was 500,152 shares, three times its normal daily volume. The company is a leading China-based provider of outsourced information technology and research and development services

General Electric (NYSE: GE) Wednesday traded in 47,906,318shares, its normal share average around 57,468,400. Shares nudged up 2.84 percent to $16.28. GE Healthcare announced today a research agreement to collaborate with Janssen Pharmaceutica NV, L.L.C. (Janssen) to identify a biosignature related to Alzheimer’s disease.

Mitel Networks Corp. (NasdaqGM: MITL) in Wednesday afternoon trading, fell 11.31 percent to $5.80, on volume of 326,519 shares, far greater than its the full-day average of 57,628. The Ontario-based MITL is a leading provider of unified communications (UC) software solutions.

Tags: , , , , , , ,
Posted in Technology Stocks | No Comments »

DNN gains ground, MOT sells widely, OREX falters

Wednesday, December 1st, 2010

Denison Mines Corp. (AMEX: DNN) climbed in price 7.42 percent to $3.33 early Wednesday afternoon. Volume was 4,929,037 shares, twice-and-a-half its normal daily volume.

Motorola Corp. (NYSE: MOT) proved quite the popular stock early Wednesday, trading in 33,997,244 shares, its normal share average around 25,960,500 for a full day. Shares in the electronics maker improved 5.55 percent to $8.09. Motorola said late Tuesday that it will split into two entities in January; Motorola Mobility Holdings, including the mobile phone and television set-top box operations, and Motorola Solutions, which will include other communications devices used in government and industry, like bar-code scanners and walkie-talkies.

Orexigen Therapeutics Inc. (NasdaqGM: OREX) fell in price 9.25 percent to $4.71. Volume of 1,798,407 shares nipped ahead the stock’s full-day average. The San Diego-based company brings its weight-loss drug Contrave to an FDA panel next week

Tags: , , , , , , , ,
Posted in Energy Stocks, Technology Stocks | No Comments »

AMRN flies on positive tests, C sells widely, CEU staggers

Monday, November 29th, 2010

Amarin Corp. PLC (NasdaqCM: AMRN) enjoyed a gain of gained 58.03 percent in price early Monday to $5.61. Volume in the first hour was a staggering 17,200,902 shares, trampling its three-month average share volume of 767,131. The Connecticut and Ireland-based pharmaceutical company today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

Citigroup Inc. (NYSE: C) was among Monday morning’s volume leaders, trading in 104,926,884 shares, nearly a quarter of its normal daily volume of 117,592,265 shares, with its three-month average share volume pegged at 464,971,000. The banking behemoth upped its price by 0.97 percent to $4.15. C today announced that it has won a mandate to provide third-party securities lending services for Global X Funds’ family of exchange traded funds.

China Education Alliance Inc. (NYSE: CEU) fell in price early Tuesday by 12.7 percent to $3.85. Volume was 165,878 shares, its three-month average share volume not available at press time. CEU is a leading China-based company experiencing fast-growing, offering high-quality education resources and services to students ages 6 to 18 and adults (university students and professionals) ages 18 and over.

Tags: , , , , , , , ,
Posted in Financial Stocks | No Comments »

EX excels, SIRI dishes widely, ASTM falls

Thursday, November 18th, 2010

Exelixis Inc. (NasdaqGS: EXEL) improved in price by 29.66 percent in Thursday afternoon trade to $6.12 Volume of 11,806,150 shares proved about 12 times the stock’s three-month daily average. The drug maker Thursday reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

Sirius XM Radio Inc. (NasdaqGS: SIRI) was a volume leader Thursday afternoon, with 47,602,492 shares changing hands, against its usual daily volume of 75,126,200 shares. SIRI shares added 3.70 percent Thursday in price to $1.40.

Aastrom Biosciences Inc. (NasdaqCM: ASTM) fell in price Thursday by 22.14 percent to $3.27. Volume of 4,182,850 shares trampled over usual daily volume of 1,068,090 shares. The Michigan-based developer of expanded autologous cellular therapies today announced that an interim analysis of all 86 patients enrolled in the company’s Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

Tags: , , , , , ,
Posted in Technology Stocks | No Comments »

« Older Entries
Newer Entries »